Two drug companies have now reported highly successful results from phase III trials of COVID-19 vaccines. On November 18 Pfizer and partner BioNTech said their vaccine was 95 percent effective at preventing the disease, based on full trial results. Two days earlier Moderna reported its vaccine was 94.5 percent effective, based on interim data.
It’s probably not exactly what President Donald Trump meant when he borrowed the historic jingoistic slogan “America First” for his administration, but since early in the global COVID-19 pandemic, the U.S. has consistently held the Number One spot in coronavirus cases and deaths. It took less than two months for these numbers to grow from 200,000 to a mind-boggling 250,000 now.
Operation Warp Speed, a Trump administration initiative to manufacture COVID-19 vaccines as fast as possible, should be lauded as a successful endeavour in what has otherwise been a poor effort to deal with the coronavirus, experts say. "No doubt, Operation Warp Speed is a huge success," said Tinglong Dai, associate professor of Operations Management and Business Analytics at Johns Hopkins University Carey Business School in Baltimore.
Reports of spiking COVID-19 cases and related fatalities have been met with recent news of extremely promising vaccines developed by Pfizer and Moderna. With the two offerings promising 90 and 95 percent effectiveness against the virus, respectively, attention now turns to mass production and, more importantly, mass distribution. According to Anna Nagurney, Ph.D., Director of the Virtual Center for Supernetworks and professor at the Department of Operations and Information Management at the University of Massachusetts, distribution is where the biggest challenges lie.
With COVID-19 cases rising across the country, the need for a safe and reliable vaccine is increasing. Both Pfizer and Moderna have announced vaccine trials with more than 90% effectiveness. Creating vaccines and getting federal approval are only the first hurdles which are followed by finding ways to transport the highly-perishable vaccines to millions of Americans.
Ashley Smith
Public Affairs Coordinator
INFORMS
Catonsville, MD
[email protected]
443-757-3578
An audio journey of how data and analytics save lives, save money and solve problems.
Can we really trust AI to make better decisions than humans? A new study says … not always. Researchers have discovered that OpenAI’s ChatGPT, one of the most advanced and popular AI models, makes the same kinds of decision-making mistakes as humans in some situations—showing biases like overconfidence of hot-hand (gambler’s) fallacy—yet acting inhuman in others (e.g., not suffering from base-rate neglect or sunk cost fallacies).
The genetic testing company 23andMe, which holds the genetic data of 15 million people, declared bankruptcy on Sunday night after years of financial struggles. This means that all of the extremely personal user data could be up for sale—and that vast trove of genetic data could draw interest from AI companies looking to train their data sets, experts say.
Robert F. Kennedy Jr., as the new secretary of Health and Human Services, is the nation’s de facto healthcare czar. He will have influence over numerous highly visible agencies, including the Centers for Disease Control and Prevention, the National Institutes of Health and the Food and Drug Administration, among others. Given that healthcare is something that touches everyone’s life, his footprint of influence will be expansive.
Health insurance has become necessary, with large and unpredictable health care costs always looming before each of us. Unfortunately, the majority of people have experienced problems when using their health insurance to pay for their medical care. Health insurance serves as the buffer between patients and the medical care system, using population pooling to mitigate the risk exposure on any one individual.
During this podcast Handfield addressed various topics, including: the current state of the supply chain; steps and actions shippers should consider related to tariffs; how the supply chain is viewed; the need for supply chain resiliency; and supply chain risk mangement planning, among others.
Oklahoma State University's Sunderesh Heragu joins LiveNOW's Austin Westfall to discuss the evolving economic landscape after President Trump implemented tariffs on some of our biggest trade partners. Most tariffs have been halted for now -- but not with China. Beijing and the White House have levied steep tariffs on each other. Trump announced that tariffs on China would reach 145 percent. In response, China imposed 125 percent tariffs on U.S.-imported goods.
Twenty years ago, few people would have been able to imagine the energy landscape of today. In 2005, US oil production, after a long decline, had fallen to its lowest levels in decades, and few experts thought that would change.
In the case of upgrading electrical and broadband infrastructure, new analysis from the University of Massachusetts Amherst reveals {that a} “dig once” strategy is almost 40% more economical than changing them individually.